US7045624B2 - Compounds and their uses - Google Patents

Compounds and their uses Download PDF

Info

Publication number
US7045624B2
US7045624B2 US10/664,367 US66436703A US7045624B2 US 7045624 B2 US7045624 B2 US 7045624B2 US 66436703 A US66436703 A US 66436703A US 7045624 B2 US7045624 B2 US 7045624B2
Authority
US
United States
Prior art keywords
hydroxy
groups
amino
alkyl
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US10/664,367
Other languages
English (en)
Other versions
US20040067970A1 (en
Inventor
Alison Jane Foster
Cornelius Paul Erik Van Der Logt
Erwin Werner Tareilus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Conopco Inc
Original Assignee
Conopco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conopco Inc filed Critical Conopco Inc
Assigned to CONOPCO, INC. reassignment CONOPCO, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FOSTER, ALISON JAYNE, VAN DER LOGT, CORNELIS PAUL ERIK, TAREILUS, ERWIN WERNER
Publication of US20040067970A1 publication Critical patent/US20040067970A1/en
Priority to US11/328,534 priority Critical patent/US20060106217A1/en
Application granted granted Critical
Publication of US7045624B2 publication Critical patent/US7045624B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/20—Synthetic spices, flavouring agents or condiments
    • A23L27/204—Aromatic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/20—Synthetic spices, flavouring agents or condiments
    • A23L27/205—Heterocyclic compounds
    • A23L27/2054—Heterocyclic compounds having nitrogen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/24—Thermal properties
    • A61K2800/244—Endothermic; Cooling; Cooling sensation

Definitions

  • the invention relates to compounds which are capable of producing a cooling sensation when they are brought into contact with the human body. Such compounds have applications in many fields, particularly in oral and personal hygiene products and foodstuffs.
  • Tetrahydropyrimidine-2-one compounds are known to be useful in pharmaceutical preparations.
  • U.S. Pat. No. 3,821,221 discloses a number of such compounds, and their effect as central nervous system stimulants or depressants. The compounds are said to be of value for therapeutic applications as potential psychotropic drugs.
  • icilin also known as AG-3-5, chemical name 1-[2-hydroxyphenyl]-4-[2-nitrophenyl]-1,2,3,6-tetrahydropyrimidine-2-one
  • icilin also known as AG-3-5, chemical name 1-[2-hydroxyphenyl]-4-[2-nitrophenyl]-1,2,3,6-tetrahydropyrimidine-2-one
  • menthol (2-isopropyl-5-methyl-cyclohexanol), which has been extensively applied as an additive in, for example, foodstuffs and oral hygiene products. It is used primarily because it elicits a sensation of coolness in the mouth, and because it has a pleasing mint flavour and odour.
  • the cooling effect of menthol is due to the action of menthol on the nerve endings of the human body which detect hot and cold stimuli. In particular, menthol is believed to activate cold receptors on nerve endings.
  • the use of menthol is limited by its strong minty smell and relative volatility.
  • icilin was capable of producing the same cooling effect as menthol.
  • Icilin has a number of advantages over menthol, for example it is more potent, and has a lower acute toxicity, due to its lack of anaesthetic properties. Icilin was considered to be a particularly useful compound for pharmacological applications because it lacks the flavour and odour of menthol and is not readily absorbed through the skin.
  • icilin has not been disclosed as a replacement for menthol for non-pharmaceutical applications.
  • R 1 and R 2 are independently selected from hydrogen or halogen atoms; hydroxy, cyano, nitro, mercapto, carbonyl, sulfone and carboxy groups; or optionally substituted alkyl, alkenyl, alkoxy, alkylthio, aryl, aryloxy, arylthio, amino, siloxy, ester and heterocyclic groups, with the proviso that when R 1 is 2-hydroxyphenyl, R 2 is other than 3-nitrophenyl.
  • X is a hydrogen or halogen atom, or an alkyl or alkoxy group
  • Y is hydroxy or alkoxy
  • n is 0, 1, 2 or 3, with the proviso that when n is 1 and Y is hydroxy, X is alkyl or hydroxy.
  • a third embodiment of the invention provides a composition comprising a compound of formula [I]:
  • R 1 and R 2 ar independently selected from hydrogen or halogen atoms; hydroxy, cyano, nitro, mercapto, carbonyl, sulfone and carboxy groups; or optionally substituted alkyl, alkenyl, alkoxy, alkylthio, aryl, aryloxy, arylthio, amino, siloxy, ester and heterocyclic groups.
  • a fourth embodiment of the present invention provides a method of imparting a cooling sensation to a human comprising administering, preferably orally, to said human, a compound according to Formula [I]:
  • R 1 and R 2 are independently selected from hydrogen or halogen atoms; hydroxy, cyano, nitro, mercapto, carbonyl, sulfone and carboxy groups; or optionally substituted alkyl, alkenyl, alkoxy, alkylthio, aryl, aryloxy, arylthio, amino, siloxy, ester and heterocyclic groups, with the proviso that when R 1 is 2-hydroxyphenyl, R 2 is other than 3-nitrophenyl.
  • alkyl represents a linear or cyclic saturated hydrocarbon which may be straight-chain or branched, and preferably contains up to 20 carbon atoms.
  • alkenyl represents a linear or cyclic, straight-chain or branched unsaturated hydrocarbon which preferably contains up to 20 carbon atoms.
  • an alkyl group is linear, it preferably contains from 1 to 10, more preferably from 1 to 6 carbon atoms. Suitable examples include methyl, ethyl, propyl, butyl, pentyl and hexyl, and isomers thereof.
  • a C 4 group can be present in the form of n-butyl, iso-butyl, sec-butyl or tert-butyl.
  • an alkyl group is cyclic, it preferably contains from 5 to 10 carbon atoms, and may be, for example, cyclopentyl, cyclohexyl, cycloheptyl, decalin or adamantyl.
  • Alkoxy and alkylthio represent alkyl groups linked by an oxygen atom or a sulphur atom respectively, with the alkyl portion being as defined above.
  • Haloalkyl represents an alkyl group as defined above substituted by at least one halogen atom.
  • the alkyl group comprises 1 to 6 carbon atoms, and it is preferably substituted by 1 to 6 halogen atoms, more preferably by 1 to 3 halogen atoms.
  • Typical examples include methyl, ethyl and propyl groups substituted by 1 to 6 halogen atoms selected from chlorine, bromine and fluorine. Methyl groups substituted by 1 to 3 of these halogen atoms are preferred, for example trifluoromethyl and trichloromethyl.
  • Aryl represents a hydrocarbon comprising at least one aromatic ring, and may contain from 5 to 18, preferably from 6 to 14, more preferably from 6 to 10, and most preferably 6 carbon atoms.
  • Typical aryl groups include phenyl, naphthyl, phenanthryl, anthracyl, indenyl, azulenyl, biphenylenyl, and fluorenyl groups.
  • Particularly preferred aryl groups include phenyl, naphthyl and fluorenyl, with phenyl being most preferable.
  • Aryloxy and arylthio represent aryl groups linked by an oxygen atom or a sulphur atom respectively, with the aryl portion being as defined above.
  • Amino represents a group having the general formula —NR′R′′ where R 40 and R′′ are independently selected from hydrogen atoms and alkyl groups, When R′ and R′′ are alkyl groups they preferably contain from 1 to 10, more preferably from 1 to 4, carbon atoms.
  • Possible amino groups include —NH 2 , methyl amino (i.e. —NHMe), ethyl amino, propyl amino, butyl amino, sec-butyl amino, tert-butyl amino, pentyl amino, hexyl amino, heptyl amino, octyl amino, stearyl amino, dimethyl amino (i.e.
  • Siloxy represents a group of general formula —OSiR 3 , where each R group is independently selected from the group consisting of a hydrogen atom and an alkyl group.
  • the alkyl group preferably has from 1 to 6, more preferably 1 to 4, carbon atoms
  • ester also known as alkoxycarbonyl
  • R is a hydrogen atom or an alkyl group.
  • the alkyl group has from 1 to 6, more preferably from 1 to 4, carbon atoms.
  • heterocyclic represents groups having between 3 and 20, more preferably between 3 and 10, carbon atoms and having one or more 4, 5, 6 or 7 member saturated or unsaturated rings containing 1, 2 or 3 oxygen, nitrogen or sulphur atoms.
  • Heterocyclic groups containing saturated rings include groups based on pyrrolidine, piperidine, tetrahydro-thiophene, dithiolane, oxathiolane, oxazolidine, oxazinane, oxathiane, tetrahydro-thiopyran, tetrahydro-pyran, dioxolane, dioxane, thiazinane, dithiane, thiazolidine, imidazolidine, hexahydro-pyrimidine and tetrahydro-furan.
  • Heterocyclic groups containing aromatic rings include thienyl, benzothienyl, naphthothienyl, thianthrenyl, furyl, pyranyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxathinyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolizinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinazolinyl, cinnolinyl, pteridinyl, carbazolyl, carbonlinyl, phenanthridinyl, acridinyl, perimidinyl, perimidinyl,
  • halogen represents any halogen atom selected from fluorine, chlorine, bromine and iodine, with fluorine and chlorine being preferred.
  • the substituent groups may include halogen atoms, hydroxy, thiol, cyano, amino, silyl, nitro, alkyl, haloalkyl, cycloalkyloxy, alkoxy, haloalkoxy, alkoxycarbonyl, carboxyl, carbonyl, alkanoyl, alkylthio, alkylsulphinyl, sulphinyl, alkylsulphonyl, sulphonato, alkylsulphonato, aryl, arylalkyl, alkaryl, aryloxy, arylsulphinyl, arylsulphonyl, arylsulphonato, sulphonamide, carbamoyl, carbamido, alkylamido, alkenyl, alkenyloxy and alkynyl, as well as heterocyclic groups.
  • the preferred optional substituents are halogen atoms, and nitro, hydroxy, alkyl, haloalkyl, alkoxy and carboxy groups.
  • the optional substituent is an alkyl, haloalkyl or alkoxy group
  • the alkyl portion of the substituent preferably contains from 1 to 6 carbon atoms, and is preferably linear.
  • Particularly preferred optional substituents are chlorine atoms, and nitro, hydroxy, methyl, ethyl, tertiary butyl and methoxy groups.
  • the compounds and compositions disclosed in the present invention have the ability to produce a cooling sensation when in contact with the skin and/or mucosal membrane of a human or animal body.
  • a “cooling sensation” as used throughout is thus Intended to mean any sensation of coolness which is perceived by human or animal body.
  • Such a cooling sensation is analogous to the sensation produced by compounds such as menthol, and/or the sensation elicited when cold-sensitive receptors, such as those identified in McKemy et al, Nature, Vol. 416, 2002, 52–58, are stimulated.
  • a cooling sensation is desirable in many different applications.
  • the compounds and compositions of the invention have applications in a number of personal hygine, oral hygiene and food product compositions.
  • Personal hygiene applications include lotions, shaving cream, post shaving preparations, shampoos, conditioners, facial cleansers, soaps, bath oils and foams, antiperspirants, deodorants.
  • Oral hygiene applications include toothpastes, mouthwashes, dental floss, chewing gum and breath fresheners.
  • Foodstuff applications include beverages, spreads, ice-creams and confectionery. Possible other applications where a cooling sensation may be desirable include pharmaceutical products (for example chewable pharmaceutical products, or throat lozenges), tobacco products, insect repellents and cosmetics.
  • a first embodiment of the invention provides the use of a compound of Formula [I] on order to produce a cooling sensation with the proviso that when R 1 is 2-hydroxyphenyl, R 2 is other than 3-nitrophenyl.
  • preferred R 1 groups include optionally substituted alkyl or aryl groups.
  • the alkyl group can be a linear group such as a C 1-10 aliphatic chain, or a cyclic group, such as a C 3-10 cyclic hydrocarbon. It is preferred that R 1 is an optionally substituted aryl or cyclic hydrocarbon group, such as a phenyl or cyclohexyl group.
  • the preferred R 2 groups include hydrogen atoms, or optionally substituted alkyl or aryl groups.
  • the R 2 group can be a linear, aliphatic chain, or a cyclic hydrocarbon, as for R 1 .
  • the preferred groups are optionally substituted aryl and cyclic hydrocarbon groups, with phenyl and cyclohexyl being particularly favoured.
  • each X and Y is independently a halogen atom or an alkyl, alkenyl, haloalkyl, alkoxy, hydroxy, thiol, carboxy, nitro, sulphonamide, sulphonato, sulphonyl, alkoxycarbonyl, carbonyl or amino group, and m and n are independently 0, 1, 2 or 3, with the proviso that when n is 1, m is 1 and Y is a hydroxy group in the ortho position, X is other than a nitro group in the meta position.
  • substituent X or Y groups contain an alkyl portion (e.g. the alkyl portion of haloalkyl), this alkyl portion preferably contains from 1 to 6 carbon atoms. In the case of an alkenyl group, this preferably contains from 2 to 6 carbon atoms.
  • X can be selected from any of the groups listed above, with hydrogen and halogen atoms, and nitro, hydroxy, C 1-6 alkyl, C 1-6 haloalkyl and C 1-6 alkoxy groups being preferred.
  • the number of X substituents can vary between 0 and 3, and the point of substitution of the phenyl ring may also be varied. It is preferred that there is a single substituent on the phenyl ring, i.e. where m is 1. In this case the substituent can be present in the ortho, meta or para position, relative to the point of attachment of the phenyl ring to the rest of the molecule containing the cyclic urea group. The optimal point of attachment will depend on a number of factors, such as the nature of the substituent and its electron-donating or electron-withdrawing effect. Particularly useful compounds include those where the substituent is present in the meta position.
  • Y can be selected from any of the groups listed above, with hydrogen, hydroxy, C 1-6 alkyl, C 1-6 haloalkyl and C 1-6 alkoxy groups being preferred.
  • the number of Y substituents can vary between 0 and 3, and the point of substitution of the phenyl ring may also be varied. It is preferred that there is a single Y substituent (i.e. where n is 1), which may be present in the ortho, meta or para position, relative to the point of attachment of the phenyl ring to the rest of the molecule containing the cyclic urea group.
  • Particularly useful compounds include those where the single Y substituent is present in the ortho position.
  • a particularly preferred compound in accordance with the first embodiment of the invention is one according to general formula [III]:
  • X and Y are independently selected from a halogen atom or an alkyl, alkenyl, haloalkyl, alkoxy, hydroxy, thiol, carboxy, nitro or amino group, with the proviso that when Y is a hydroxy group, X is other than a nitro group. It is preferred that X is a hydrogen or halogen atom, or a nitro, hydroxy, C 1-6 alkyl or C 1-6 alkoxy group. Particularly preferred groups include halogen atoms, and methyl, ethyl, methoxy and ethoxy groups. The preferred halogen atom is chlorine.
  • Preferred compounds include 1-(2′-methoxyphenyl)-4-(3′′-nitrophenyl-1,2,3,6-tetrahydropyrimidine-2-one, 1-phenyl-4-(3′′-nitrophenyl)-1,2,3,6-tetrahydropyrimidine-2-one, 1-(2′-methoxyphenyl-4-(3′′-chlorophenyl)-1,2,3,6-tetrahydropyrimidine-2-one, 1-phenyl-4-(3′′-chlorophenyl)-1,2,3,6-tetrahydropyrimidine-2-one, 1-(2′-methylphenyl)-4-(3′′-nitrophenyl)-1,2,3,6-tetrahydropyrimidine-2-one, 1-(2′-methoxyphenyl-4-(3′′-methoxyphenyl)-1,2,3,6-tetrahydropyrimidine-2-one
  • the compounds may be used alone, or in a composition in combination with another substance or substances such as a carrier.
  • additional substances such as a carrier.
  • the nature of these additional substances, and the relative proportions of components of the composition will depend on a number of factors, such as the specific use for which the composition is employed.
  • the compositions may be used in a variety of applications, such as those discussed above. Particularly preferred uses include personal hygiene products such as deodorant, shower gel and skin cream; oral hygiene products such as toothpastes and mouthwashes; and foodstuffs, such as beverages, ice-creams, confectionery and spreads.
  • the second embodiment of the invention encompasses compounds of general formula [IV] recited above, or a salt thereof, wherein X is a hydrogen or halogen atom, or a hydroxy, nitro, alkyl or alkoxy group; Y is hydrogen, hydroxy, haloalkyl, nitro or alkoxy, and n is 0, 1, 2 or 3, with the proviso that when n is 1 and Y is hydroxy, X is alkyl or hydroxy. It is preferred that when n is 1 and Y is hydroxy, X is not a halogen atom. According to one aspect of this embodiment, it is preferred that when n is 1 and Y is hydroxy, X is alkyl or hydroxy. Particularly preferred in this aspect is where Y is hydroxy.
  • Y is haloalkyl, particularly when Y is nitro.
  • a particularly preferred haloalkyl is halomethyl, most preferably trifluoromethyl.
  • the number of Y substituents may vary between 0 and 3, and the substituents can be present in any position. However, it is preferred that there is a single Y substituent, i.e. where n is 1. This substituent may be present in the ortho, meta or para position, relative to the point of attachment of the phenyl ring to the rest of the molecule.
  • the optimal position of the substituent will depend on a number of factors, such as the nature of the substituent and its electron-donating or electron-withdrawing effect. The ortho position is preferred.
  • particularly preferred compounds in accordance with the second embodiment are those according to the general formula [V]:
  • Y is a hydroxy group or a methoxy group.
  • X is preferably a hydrogen or halogen atom, or a hydroxy, C 1-6 alkyl or C 1-6 alkoxy group, providing that where Y is hydroxy, X is alkyl or hydroxy.
  • Particularly preferred X groups include halogen atoms, and methyl, ethyl, methoxy and ethoxy groups. Chlorine atoms and methoxy groups are most preferred.
  • the compounds of this second embodiment of the invention may be used in a variety of applications, such as those discussed above. In particular they may be used in applications similar to those described above in relation to the first embodiment of the invention, for example in personal hygiene products such as deodorant, shower gel and skin cream; oral hygiene products such as mouthwash and toothpaste; and food products.
  • the compounds may have particularly useful applications in foodstuffs such as beverages, spreads, confectionery and ice-cream.
  • the third embodiment of the invention provides novel compositions comprising compounds of the invention.
  • the compositions can be used for a number of applications where a cooling sensation is desirable.
  • applications may include the fields of personal hygiene products (including lotions, shaving cream, post shaving preparations, shampoos, conditioners, facial cleansers, soaps, bath oils and foams, antiperspirants and deodorants); oral hygiene products (including toothpastes, mouthwashes, dental floss, chewing gum and breath fresheners); food products (including beverages, spreads, ice-creams and confectionery); and other applications where a cooling sensation may be desirable (including pharmaceutical products such as chewable pharmaceutical products or throat lozenges, tobacco products, insect repellents and cosmetics).
  • compositions for use as toothpastes, mouthwashes and food products such as confectionery, beverages, spreads and ice-cream.
  • the specific nature of the composition e.g. the nature of the additional components, the relative proportions of the components and the physical nature of the composition will depend on the particular application.
  • a composition such as a toothpaste, mouthwash or food product composition, comprising a compound of formula [I]:
  • R 1 and R 2 are independently selected from hydrogen or halogen atoms; hydroxy, cyano, nitro, mercapto, carbonyl, sulfone and carboxy groups; or optionally substituted alkyl, alkenyl, alkoxy, alkylthio, aryl, aryloxy, arylthio, amino, siloxy, ester and heterocyclic groups.
  • the compound of formula [I] is other than a compound where R 1 is 2-hydroxyphenyl and R 2 is 3-nitrophenyl.
  • the compound of formula [I] can be any compound resulting from a selection of R 1 and R 2 from the list given above. However, preferred compounds are those which have already been discussed in relation to the first embodiment of the invention above.
  • a composition such as a toothpaste, mouthwash or food product composition, comprising a compound of formula [IV] as discussed above in relation to the second embodiment of the invention.
  • the compound which is capable of producing a cooling sensation is preferably present in an amount of from 0.0001% to 3%, eg from 0.001% to 3% by weight, based on the total weight of the composition.
  • An especially preferred range is from 0.0001% to 0.3% by weight.
  • the compound may present in an amount of from 0.0003% to 0.1% or from 0.003% to 0.1%.
  • Dimethylamino-m-chloropropiophenone hydrochloride (74.9 g, 0.30 mol) was dissolved in 50% aqueous ethanol (700 ml) at reflux. 2-Aminophenol (32.9 g, 0.30 mol) was then added and the resulting red solution was refluxed for a further 2 hours. The reaction mixture was allowed to cool to room temperature and then extracted twice with ethyl acetate (2 ⁇ 100 ml). Note that brine was also added at this point to allow the two layers to separate effectively). The organic extracts were combined and an excess of concentrated hydrochloric acid (47 ml) was added. The solution was concentrated in vacuo and then allowed to cool. The precipitate that formed was filtered of, washed with diethyl ether and dried in vacuo to yield a cream powder (38.1 g, 40%).
  • ⁇ -(o-Hydroxyanilino)-m-chloropropiophenone hydrochloride (4.0 g, 0.013 mol) was taken up in acetic acid (50 ml) and the mixture was warmed to 60° C. Potassium cyanate (2.6 g, 0.032 mol) was added and the resulting reaction mixture was kept at 60° C. for a further 30 minutes and then allowed to cool to room temperature. Water (100 ml) was then added and the suspension was extracted with ethyl acetate (3 ⁇ 30 ml) and the combined organic extracts were washed successively with 10% sodium hydroxide solution (100 ml), 10% hydrochloric acid (100 ml) and brine (100 ml). The organic extract was the dried (Na 2 SO 4 ), concentrated in vacuo and allowed to cool overnight. The precipitate that formed was filtered off and washed with diethyl ether to yield a cream powder (1.6 g, 41%).
  • the compounds tested include a number according to the following general formula:
  • the compounds were dissolved in DMSO by ultrasonication to a 0.1 M solution. 5 ⁇ l of this stock was added to 5 mg of cyclodextrin and 5 ml of 140 Na-tyrode, to achieve a 100 ⁇ M final test concentration.
  • Neurons from trigeminal ganglia of Wistar rats were prepared as described in U.S. Pat. No. 5,811,256. After 24 hours of cultivation, the responsiveness of the neurons to different compounds was measured according to the general procedure described by McKemy et al (Nature, Vol. 416, 2002, 52–58). The test protocol described by McKemy was modified slightly, by using the fluorescent Ca 2+ indicator Fura-2. Detection of the cellular fluorescence signals was performed by videomicroscopical analysis. The neurons were given a cold stimulus by a thermocoupling device and were subsequently tested for responsiveness to the test compounds by superfusion with solutions containing the test compounds while continuously monitoring the cellular Ca 2+ levels.
  • Compound Activity (% relative to Compound 1) 1 100 2 40 3 35 Menthol (comparative example) 42

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Confectionery (AREA)
  • Seasonings (AREA)
  • Seeds, Soups, And Other Foods (AREA)
US10/664,367 2002-09-18 2003-09-17 Compounds and their uses Expired - Fee Related US7045624B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/328,534 US20060106217A1 (en) 2002-09-18 2006-01-10 Novel compounds and their uses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0221697.6A GB0221697D0 (en) 2002-09-18 2002-09-18 Novel compouds and their uses
GB0221697.6 2002-09-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/328,534 Division US20060106217A1 (en) 2002-09-18 2006-01-10 Novel compounds and their uses

Publications (2)

Publication Number Publication Date
US20040067970A1 US20040067970A1 (en) 2004-04-08
US7045624B2 true US7045624B2 (en) 2006-05-16

Family

ID=9944340

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/664,367 Expired - Fee Related US7045624B2 (en) 2002-09-18 2003-09-17 Compounds and their uses
US11/328,534 Abandoned US20060106217A1 (en) 2002-09-18 2006-01-10 Novel compounds and their uses

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/328,534 Abandoned US20060106217A1 (en) 2002-09-18 2006-01-10 Novel compounds and their uses

Country Status (10)

Country Link
US (2) US7045624B2 (de)
EP (1) EP1546114B1 (de)
JP (1) JP4959939B2 (de)
CN (1) CN100506800C (de)
AU (1) AU2003266321A1 (de)
BR (1) BR0314447A (de)
GB (1) GB0221697D0 (de)
RU (1) RU2334741C2 (de)
WO (1) WO2004026840A1 (de)
ZA (1) ZA200502122B (de)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050090514A1 (en) * 2003-07-02 2005-04-28 Mark Reynolds Trp-p8 active compounds and therapeutic treatment methods
US20070142798A1 (en) * 2005-12-16 2007-06-21 The Procter & Gamble Company Disposable absorbent article having serviceable indicia indicating improper fit
US20090110656A1 (en) * 2007-10-31 2009-04-30 Lemke Sarah A Skin cooling composition
US20090157153A1 (en) * 2007-12-13 2009-06-18 Sarah Anne Lemke Skin cooling system
US20100297038A1 (en) * 2008-01-17 2010-11-25 Givaudan S.A. Benzimidazole Derivatives And Their Use As Cooling Agents
US8558053B2 (en) 2005-12-16 2013-10-15 The Procter & Gamble Company Disposable absorbent article having side panels with structurally, functionally and visually different regions

Families Citing this family (212)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010018579A1 (en) 1998-12-18 2001-08-30 Walter Klemp Disposable absorbent garment having stretchable side waist regions
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US20070191797A1 (en) * 2006-02-10 2007-08-16 Roe Donald C Absorbent article with sensation member
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
ES2532906T5 (es) 2002-10-25 2022-03-23 Foamix Pharmaceuticals Ltd Espuma cosmética y farmacéutica
US20070292461A1 (en) * 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
GB0229811D0 (en) * 2002-12-20 2003-01-29 Unilever Plc Compound delivery systems
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
JP2007512227A (ja) 2003-08-06 2007-05-17 セノミックス、インコーポレイテッド Ｔ１ｒヘテロオリゴマー味覚受容体、この受容体を発現する細胞株、および味覚化合物
JP2005310310A (ja) * 2004-04-23 2005-11-04 Sanyo Electric Co Ltd トラッキングバランス調整装置
US20060045953A1 (en) * 2004-08-06 2006-03-02 Catherine Tachdjian Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste enhancers
AU2005323206C1 (en) * 2005-01-04 2010-01-07 Teikoku Pharma Usa, Inc. Cooling topical patch preparation
MX2007009388A (es) * 2005-02-04 2007-09-25 Senomyx Inc Compuestos que comprenden porciones heteroarilo unidas y su uso como modificadores del sabor unami, saborizantes y mejoradores del sabor para composiciones comestibles.
US7806880B2 (en) * 2005-03-18 2010-10-05 The Procter & Gamble Company Pull-on wearable article with informational image
US20060264858A1 (en) * 2005-05-20 2006-11-23 Roe Donald C Multi-functional training garment
WO2006131203A1 (en) * 2005-06-10 2006-12-14 Unilever N.V. Oral care composition comprising a 1 , 2 , 3 , 6-tetrahydropyrimidine-2-one cooling agent
AR055329A1 (es) 2005-06-15 2007-08-15 Senomyx Inc Amidas bis-aromaticas y sus usos como modificadores de sabor dulce, saborizantes, y realzadores de sabor
US20070077331A1 (en) 2005-10-05 2007-04-05 Cadbury Adams Usa Llc. Cooling compositions
MX2008000486A (es) * 2005-10-24 2008-03-07 Teikoku Pharma Usa Inc Composiciones topicas para el alivio del dolor de n-2,3-trimetil-2-isopropilbutamida y metodos para usar las mismas.
WO2007126430A1 (en) 2005-12-23 2007-11-08 Cadbury Adams Usa Llc Compositions providing a heating sensation for oral or dermal delivery
AU2006330915B2 (en) 2005-12-23 2011-02-03 Intercontinental Great Brands Llc Compositions providing a sensation substantially similar to that provided by menthol
US20070233027A1 (en) * 2006-03-31 2007-10-04 The Procter & Gamble Company Absorbent article with sensation member
US8491558B2 (en) * 2006-03-31 2013-07-23 The Procter & Gamble Company Absorbent article with impregnated sensation material for toilet training
US8057450B2 (en) * 2006-03-31 2011-11-15 The Procter & Gamble Company Absorbent article with sensation member
US8664467B2 (en) * 2006-03-31 2014-03-04 The Procter & Gamble Company Absorbent articles with feedback signal upon urination
EP3235811B1 (de) 2006-04-21 2018-07-25 Senomyx, Inc. Verfarhen zur herstellung von oxalamiden
WO2008006236A2 (en) * 2006-07-14 2008-01-17 Givaudan Sa Benzimidazoles as cooling compounds
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
CA2671929C (en) 2006-12-04 2013-03-19 The Procter & Gamble Company Absorbent articles comprising graphics
US20100056636A1 (en) * 2006-12-20 2010-03-04 Stefan Michael Furrer N-Substituted-P-Menthane-3-Carboxamide and Uses Thereof
EP1958627A3 (de) 2007-01-04 2010-09-01 Symrise GmbH & Co. KG Verwendung bestimmter Menthyl-3-oxocarbonsäureester als physiologisch wirksame Kühlsubstanzen
PL1986473T3 (pl) * 2007-04-03 2017-07-31 Tsinghua University Organiczne urządzenie elektroluminescencyjne
EP2008530B1 (de) 2007-06-19 2011-01-19 Symrise AG Aromakomposition zum Verringern oder Unterdrücken von unerwünschtem bitteren und adstringierenden Eindruck
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
ES2395682T3 (es) 2007-08-20 2013-02-14 Symrise Ag Derivados de ácido oxálico y su uso como principios activos refrescantes fisiológicos
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
EP2242476A2 (de) 2008-01-14 2010-10-27 Foamix Ltd. Aufschäumbare pharmazeutische poloxamer-zusammensetzungen mit wirkstoffen und/oder therapeutischen zellen und verwendungen
ES2828975T3 (es) * 2008-08-26 2021-05-28 Basf Se Detección y uso de moduladores de bajo peso molecular del receptor de mentol frío TRPM8
WO2010125470A2 (en) 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
CA2769625C (en) 2009-07-29 2017-04-11 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
EP2295031B1 (de) 2009-08-05 2018-01-10 Symrise AG Verwendung von Pterocarpanen als Anti-Cellulite-Wirkstoffe
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
EP2482788B1 (de) 2009-10-02 2022-12-14 Journey Medical Corporation Topische tetracyclinzusammensetzungen
ES2551693T3 (es) 2009-10-06 2015-11-23 Symrise Ag Composición de limpieza dental que contiene mentol con percepción de amargor reducida
US9446267B2 (en) 2009-10-06 2016-09-20 Symrise Ag Products comprising a flavoring agent composition
DE102010002558A1 (de) * 2009-11-20 2011-06-01 Symrise Ag Verwendung physiologischer Kühlwirkstoffe und Mittel enthaltend solche Wirkstoffe
US9066880B2 (en) 2010-04-08 2015-06-30 Symrise Ag Use of dihydrodehydrodiisoeugenol and preparations comprising dihydrodehydrodiisoeugenol
RU2567175C2 (ru) 2010-05-11 2015-11-10 Симрайз Аг Применение рубузозида для ослабления или подавления некоторых неприятных вкусовых ощущений
EP2389922A1 (de) 2010-05-25 2011-11-30 Symrise AG Cyclohexylcarbamatverbindungen als Anti-ageing-Wirkstoffe
EP2394703B1 (de) 2010-06-14 2015-12-23 Symrise AG Kühlmischungen mit verstärkter Kühlwirkung von 5-Methyl-2-(propan-2-yl)cyclohexyl-N-ethyloxamat
US9029415B2 (en) 2010-06-14 2015-05-12 Symrise Ag Cooling mixtures with an enhanced cooling effect of 5-methyl-2-(propane-2-yl)cyclohexyl-N-ethyloxamate
EP2457554A1 (de) 2010-11-24 2012-05-30 Symrise AG Menthol enthaltende Mischung
EP2356977B1 (de) 2011-02-02 2017-12-27 Symrise AG Zubereitungen mit Holzextrakten von Gleditschien
EP2497458A1 (de) 2011-03-08 2012-09-12 B.R.A.I.N. Biotechnology Research And Information Network AG Kleinmolekülige Modulatoren des Kälte- und Mentholrezeptors TRMP8
MY157429A (en) 2011-06-24 2016-06-15 Amgen Inc Trpm8 antagonists and their use in treatments
JP2014517074A (ja) 2011-06-24 2014-07-17 アムジエン・インコーポレーテツド Ｔｒｐｍ８アンタゴニストおよび治療におけるそれらの使用
WO2013041621A1 (de) 2011-09-20 2013-03-28 Basf Se Niedermolekulare modulatoren des kälte-menthol-rezeptors trpm8 und deren verwendung
WO2013170433A1 (en) 2012-05-15 2013-11-21 The Procter & Gamble Company Absorbent article having characteristic waist end
BR112014031168B1 (pt) 2012-06-15 2018-05-02 Symrise Ag Método não terapêutico para a estimulação da biossíntese de hialuronana, composição farmacêutica ou dermatológica, e uso da mesma
WO2014005614A1 (en) 2012-07-02 2014-01-09 Symrise Ag A method of flavouring a smoking product
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
EP3552597A1 (de) 2012-08-07 2019-10-16 Symrise AG Compositions cosmétiques
EP2745878B1 (de) 2012-12-19 2023-01-25 Symrise AG Kosmetische Zubereitungen
PT2948129T (pt) 2013-01-25 2018-02-12 Wintermute Biomedical Inc Compostos terapêuticos
EP2764860A1 (de) 2013-02-06 2014-08-13 Basf Sa Cupuassufettsäureamidoamine und ihre Derivate
ES2701758T3 (es) 2013-02-27 2019-02-25 Symrise Ag Extracto de jengibre para la protección de citoblastos
EP2774481B1 (de) 2013-03-08 2018-06-13 Symrise AG Antimikrobielle Zusammensetzungen
EP2774604B1 (de) 2013-03-08 2017-08-30 Symrise AG Kosmetische Zubereitungen
EP2783578A1 (de) 2013-03-26 2014-10-01 Symrise AG Catechin Reaktionsprodukte
EP2789369B1 (de) 2013-04-14 2018-06-06 Symrise AG Eine Zubereitung zur Aufhellung von Haut und Haaren
EP2807925A1 (de) 2013-05-26 2014-12-03 Symrise AG Antimikrobielle Zusammensetzungen
EP2810934A1 (de) 2013-06-09 2014-12-10 Symrise AG Neue Succinatderivate
EP2842607B1 (de) 2013-09-02 2018-05-30 Symrise AG Eine Mischung zur Aufhellung von Haut und/oder Haaren
CN105555366B (zh) 2013-09-22 2020-12-01 西姆莱斯股份公司 海马齿苋提取物及其应用
EP2853254B1 (de) 2013-09-26 2017-11-08 Symrise AG Kosmetische Zusammensetzung zur Aufhellung von Haut und/oder Haaren
EP2859883B1 (de) 2013-10-13 2019-05-15 Symrise AG Mischungen von Aktivstoffen enthaltend acylierte Oligopeptide und Troxerutin
EP2862852B1 (de) 2013-10-18 2018-07-04 Symrise AG Harnstoffderivate für den Schutz von Stammzellen
US20160250121A1 (en) 2013-10-29 2016-09-01 Paolo Pertile Use of mono ornithine ketoglutarate (mokg)
ES2643590T3 (es) 2014-03-18 2017-11-23 Symrise Ag Dióxido de titanio revestido para reducir el efecto de blanqueamiento en la piel
EP2932858A1 (de) 2014-04-16 2015-10-21 Symrise AG Homovanillinsäure-Ester, insbesondere zum Erzielen eines Wärme- und/oder Schärfeeindrucks
EP2962678A1 (de) 2014-06-30 2016-01-06 Symrise AG Aroma- und Duftstoffzubereitungen enthaltend Acetophenon-Derivate
EP3443950A1 (de) 2014-07-30 2019-02-20 Symrise AG Prafümzubereitung
DE102014015151A1 (de) * 2014-10-13 2016-04-14 Schlenk Metallic Pigments Gmbh PVD-Metalleffektpigmentpulver
EP3023090B1 (de) 2014-11-21 2019-08-07 Symrise AG Zubereitungen
EP3045161B1 (de) 2015-01-18 2026-03-25 Symrise AG Verwendung von Wirkstoffgemischen aus 1,2-Hexandiol und 1,2-Octandiol in kosmetischen, pharmazeutischen oder dermatologischen Emulsionen
EP3081207B1 (de) 2015-04-16 2022-09-21 Symrise AG Verwendung einer liposomenzusammensetzung
EP3288534B1 (de) 2015-04-28 2020-09-23 Symrise AG Zusammensetzungen mit einem valeria extrakt
EP3297676A2 (de) 2015-05-22 2018-03-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Kombination aus trpm8-agonist und nachr-agonist zur behandlung von obesitas und verwandten erkrankungen sowie zur gewichtsreduzierung
EP3097905B1 (de) 2015-05-28 2020-11-04 Symrise AG Kosmetische zubereitungen
CN107922882A (zh) 2015-09-08 2018-04-17 西姆莱斯股份公司 香料混合物
EP3367994B1 (de) 2015-10-28 2021-05-12 Symrise AG Verfahren zur unterdrückung oder maskierung von fischgerüchen
MX379984B (es) 2015-11-15 2025-03-11 Symrise Ag Reducción de la sensación de picazón en la piel.
WO2017097434A1 (en) 2015-12-06 2017-06-15 Symrise Ag A fragrance composition
ES2855176T3 (es) 2015-12-10 2021-09-23 Symrise Ag Composición con sabor y olor estabilizados
EP4477092A3 (de) 2015-12-16 2025-02-26 Symrise AG Zusammensetzung mit stabilisiertem geschmack und/oder geruch (ii)
ES2733201T3 (es) 2015-12-21 2019-11-28 Thiocyn Gmbh Composición cosmética que comprende una combinación de sustancias activas
ES2730087T3 (es) 2016-01-13 2019-11-08 Thiocyn Gmbh Composición para el crecimiento del cabello
CN114456176B (zh) 2016-03-28 2024-08-30 因赛特公司 作为tam抑制剂的吡咯并三嗪化合物
CN109862875A (zh) 2016-03-30 2019-06-07 西姆莱斯股份公司 一种活性混合物
EP3463580B1 (de) 2016-05-23 2020-03-25 Symrise AG Ein weizenkleie extrakt in einer haarpflegemischung
EP4603149A3 (de) 2016-08-20 2025-12-24 Symrise AG Konservierende mischung
CA2978573A1 (en) 2016-09-08 2018-03-08 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
KR102637286B1 (ko) 2016-10-11 2024-02-16 시므라이즈 아게 항균 조성물들
JP7441042B2 (ja) 2016-12-02 2024-02-29 シムライズ アーゲー 化粧品ブレンド
CN106619141A (zh) * 2016-12-20 2017-05-10 天津盛易联科技股份有限公司 一种口腔科学用牙齿修复新产品及其制备方法
WO2018148763A1 (en) 2017-02-13 2018-08-16 Wintermute Biomedical, Inc. Anti-pathogenic therapeutic compositions
IT201700090929A1 (it) 2017-08-07 2019-02-07 Cutech S R L Usi cosmetici e medici di estratti del fungo Coprinus comatus per la regolazione dell’unità pilo sebacea.
DE202017007679U1 (de) 2017-08-09 2024-03-15 Symrise Ag 1,2-Alkandiole
EP3664772B1 (de) 2017-08-09 2024-03-20 Symrise AG 1,2-alkandiole und verfahren zu ihrer herstellung
WO2019037844A1 (en) 2017-08-23 2019-02-28 Symrise Ag NOVEL NATURAL BUTTER COMPOSITIONS AND USES THEREOF
CN111032015A (zh) 2017-08-23 2020-04-17 西姆莱斯有限公司 等鞭金藻种的提取物的新用途
JP7231617B2 (ja) 2017-08-31 2023-03-01 ビーエーエスエフ ソシエタス・ヨーロピア 生理学的冷涼活性成分の使用、及びそのような活性成分を含む組成物
KR102739325B1 (ko) 2017-09-27 2024-12-09 인사이트 코포레이션 Tam 억제제로서 유용한 피롤로트리아진 유도체의 염
EP3687311A1 (de) 2017-09-27 2020-08-05 Symrise AG Amide zur erzeugung eines trigeminalen effekts
JP7104149B2 (ja) 2017-10-10 2022-07-20 シムライズ アーゲー 安息香酸またはフロン酸誘導体を含有する組成物ならびにエマルションおよび泡安定性のための前記誘導体の使用
CA3078909A1 (en) 2017-10-16 2019-04-25 Takasago International Corporation Cool-sensation imparter composition containing 2,2,6-trimethylcyclohexanecarboxylic acid derivative
MX392570B (es) 2017-10-23 2025-03-24 Symrise Ag Composición de aroma.
WO2019170222A1 (en) 2018-03-06 2019-09-12 Symrise Ag Encapsulated active substance deposition on hairs and textile
US12016944B2 (en) 2018-03-08 2024-06-25 Symrise Ag Mixtures comprising a protein extract for the treatment of human skin and/or hair
WO2019206404A1 (en) 2018-04-24 2019-10-31 Symrise Ag Core-shell capsules prepared with linear and cyclic aliphatic polyisocyanates
US11241438B2 (en) 2018-06-29 2022-02-08 Incyte Corporation Formulations of an AXL/MER inhibitor
WO2020015816A1 (de) 2018-07-16 2020-01-23 Symrise Ag Zusammensetzung zur substitution von zucker in backwaren
US12193441B2 (en) 2018-08-27 2025-01-14 Symrise Ag Antimicrobial mixtures comprising at least one hydroxyphenone derivative
AU2018441463B2 (en) 2018-09-14 2024-11-14 Symrise Ag A hair care composition
CA3113475A1 (en) 2018-09-20 2020-03-26 Symrise Ag Compositions comprising odorless 1,2-pentanediol
CN113164420B (zh) 2018-10-01 2025-01-03 温特穆特生物医学公司 治疗组合物
WO2020069762A1 (en) 2018-10-05 2020-04-09 Symrise Ag A method for fighting female body odors
KR20210089197A (ko) 2018-11-02 2021-07-15 시므라이즈 아게 UV 필터들의 액체이고 투명한 블렌드 (blend)
MX2021005418A (es) 2018-11-08 2021-07-06 Symrise Ag Una composicion a base de agente tensioactivo antimicrobiano.
US20220168198A1 (en) 2019-01-17 2022-06-02 Symrise Ag An antimicrobial mixture
US20220071933A1 (en) 2019-01-18 2022-03-10 Symrise Ag Combination remedy
EP3938054A1 (de) 2019-03-11 2022-01-19 Symrise AG Verfahren zur verbesserung der leistung eines duftstoffes oder eines duftstoffgemisches
CN113710331B (zh) 2019-03-12 2024-03-22 西姆莱斯股份公司 一种抗微生物混合物
KR20210142707A (ko) 2019-03-22 2021-11-25 시므라이즈 아게 식물 펩타이드류 및 그의 용례들 (ii)
WO2020192865A1 (en) 2019-03-22 2020-10-01 Symrise Ag Plant peptides and their applications
CN113993500B (zh) 2019-06-13 2025-08-12 德国德之馨香精香料公司 一种清凉制剂
US20220354772A1 (en) 2019-07-02 2022-11-10 Symrise Ag Blend of beeswax and a lactylate ester
US12421474B2 (en) 2019-09-04 2025-09-23 Symrise Ag Perfume oil mixture
CN114727914A (zh) 2019-10-16 2022-07-08 西姆莱斯股份公司 用于将化妆品活性物质间接转移至皮肤的制品
PH12022552347A1 (en) 2020-03-06 2024-01-29 Incyte Corp Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
WO2021228352A1 (en) 2020-05-11 2021-11-18 Symrise Ag A fragrance composition
JP7641991B2 (ja) 2020-05-11 2025-03-07 シムライズ アーゲー 固体粘着性組成物
CN115279414A (zh) 2020-05-22 2022-11-01 弗门尼舍有限公司 用于减少咸味的组合物及其用途
BR112022016411A2 (pt) 2020-06-03 2022-10-11 Firmenich & Cie Composições para reduzir gostos desagradáveis e usos das mesmas
EP4171266A1 (de) 2020-06-24 2023-05-03 Firmenich SA Süssstoffzusammensetzungen und verwendungen davon
WO2022013163A1 (en) 2020-07-14 2022-01-20 Firmenich Sa Reduction of undesirable taste notes in oral care products
ES2985530T3 (es) 2020-08-06 2024-11-06 Symrise Ag Microcápsulas de poliurea/poliuretano
BR112023001890A2 (pt) 2020-08-06 2023-03-07 Symrise Ag Processo para a preparação de microcápsulas
JP7546145B2 (ja) 2020-08-06 2024-09-05 シムライズ アーゲー 生分解性ポリ尿素／ポリウレタンマイクロカプセル
EP4125428A1 (de) 2020-09-22 2023-02-08 Firmenich SA Methylsalicylatfreie wintergrünaromazusammensetzungen
WO2022111793A1 (en) 2020-11-24 2022-06-02 Symrise Ag Medicament for accelerated wound healing
WO2022112432A1 (en) 2020-11-29 2022-06-02 Firmenich Sa Compositions that reduce peroxide off taste and uses thereof
WO2022111829A1 (en) 2020-11-30 2022-06-02 Symrise Ag Essential oils of citrus fruits for use as medicament for induced, increased and/or accelerated autophagy in human keratinocytes
WO2022122122A1 (en) 2020-12-08 2022-06-16 Symrise Ag Medicament for fighting inflammatory conditions of human skin (i)
WO2022122135A1 (en) 2020-12-09 2022-06-16 Symrise Ag Compositions comprising (bio)-alkanediols with antimicrobials for product protection
WO2022122140A1 (en) 2020-12-09 2022-06-16 Symrise Ag Compositions comprising one or more (bio)-alkanediols with active ingredients
WO2022122131A1 (en) 2020-12-09 2022-06-16 Symrise Ag Compositions comprising lipophilic compounds and one or more (bio)-alkanediols
WO2022122133A1 (en) 2020-12-09 2022-06-16 Symrise Ag Compositions comprising uv-filters and one or more (bio)-alkanediols
US20240050337A1 (en) 2020-12-09 2024-02-15 Symrise Ag A mixture comprising 1,2-alkanediols
WO2022122134A1 (en) 2020-12-09 2022-06-16 Symrise Ag Compositions with (bio)-alkanediols and cooling agents
WO2022122132A1 (en) 2020-12-09 2022-06-16 Symrise Ag Compositions comprising natural polymers and one or more (bio)-alkanediols
WO2022122136A1 (en) 2020-12-09 2022-06-16 Symrise Ag Compositions comprising one or more (bio)-alkanediols with antioxidants
WO2022122137A1 (en) 2020-12-09 2022-06-16 Symrise Ag Compositions comprising antimicrobials and (bio)-alkanediols for skin protection
WO2022122138A1 (en) 2020-12-09 2022-06-16 Symrise Ag Multifunctional compound mixtures comprising multiple (bio)-alkanediols
WO2022122167A1 (en) 2020-12-11 2022-06-16 Symrise Ag Medicament for preventing or treating pathologic conditions of human skin (i)
WO2022128054A1 (en) 2020-12-14 2022-06-23 Symrise Ag Medicament for fighting inflammatory conditions of human skin (iv)
WO2022128051A1 (en) 2020-12-14 2022-06-23 Symrise Ag Medicament for fighting inflammatory conditions of human skin (ii)
WO2022128052A1 (en) 2020-12-14 2022-06-23 Symrise Ag Medicament for fighting inflammatory conditions of human skin
WO2022128057A1 (en) 2020-12-14 2022-06-23 Symrise Ag Medicament for prevention and treatment of collagen degradation in human connecting tissue
WO2022128050A1 (en) 2020-12-14 2022-06-23 Symrise Ag Medicament for fighting inflammation and pain
WO2022128048A1 (en) 2020-12-14 2022-06-23 Symrise Ag Medicament for preventing or treating pathologic conditions of human skin
EP4251122B1 (de) 2021-01-13 2025-03-12 Firmenich Incorporated Zusammensetzungen zur verstärkung der kühlwirkung
WO2022161593A1 (en) 2021-01-26 2022-08-04 Symrise Ag Medicament for accelerated wound healing
WO2022171292A1 (en) 2021-02-12 2022-08-18 Symrise Ag Medicament for prevention and treatment of hyperpigmentation
WO2022214187A1 (en) 2021-04-08 2022-10-13 Symrise Ag An o/w emulsion base and emulsions comprising the same
US20240173227A1 (en) 2021-04-13 2024-05-30 Symrise Ag A fragrance mixture containing isocitronellol
EP4326251A1 (de) 2021-04-19 2024-02-28 Symrise AG Zusammensetzungen mit cannabidiol und optional bisabolol
EP4083050A1 (de) 2021-05-01 2022-11-02 Analyticon Discovery GmbH Mikrobielle glykolipide
JP2024522284A (ja) 2021-05-28 2024-06-13 フィルメニッヒ インコーポレイテッド 清涼効果を増強する組成物
BR112023022598A2 (pt) 2021-06-24 2024-01-16 Firmenich & Cie Composições para cuidados orais
JP2024529283A (ja) 2021-06-30 2024-08-06 フイルメニツヒ ソシエテ アノニム 速乾性の香料組成物
EP4376995A1 (de) 2021-07-30 2024-06-05 Symrise AG Biobasierte kern-schale-mikrokapseln
WO2023117643A1 (en) 2021-12-23 2023-06-29 Firmenich Sa Antimicrobial composition having encapsulated colorant
JP2025505605A (ja) 2022-02-02 2025-02-28 シムライズ アーゲー マイクロカプセルの製造方法
WO2023147855A2 (de) 2022-02-02 2023-08-10 Symrise Ag Verfahren zur herstellung von mikrokapseln
CN119604269A (zh) 2022-07-07 2025-03-11 弗门尼舍公司 增强清凉效果的组合物
EP4554572A2 (de) 2022-07-11 2025-05-21 Symrise AG Mischungen und verwendungen von (2e)-3-(1,3-benzodioxol-5-yl)-n-phenyl-n-(tetrahydro-3-furanyl)-2-propenamid
WO2024028515A1 (en) 2022-08-05 2024-02-08 Symrise Ag Composition comprising a uv-filter stabilizer
WO2024027928A1 (en) 2022-08-05 2024-02-08 Symrise Ag Composition with improved spf and uva photoprotection
WO2024027926A1 (en) 2022-08-05 2024-02-08 Symrise Ag Composition comprising a uv-filter stabilizer
CN119604270A (zh) 2022-08-05 2025-03-11 西姆莱斯股份公司 包含抗微生物促进剂的组合物
CN119744164A (zh) 2022-08-05 2025-04-01 西姆莱斯股份公司 气味和着色剂稳定的组合物
EP4565187A1 (de) 2022-08-05 2025-06-11 Symrise AG Zusammensetzung mit verbessertem spf- und uva-lichtschutz
WO2024027930A1 (en) 2022-08-05 2024-02-08 Symrise Ag Compositions comprising an antimicrobial boosting agent
WO2024027931A1 (en) 2022-08-05 2024-02-08 Symrise Ag Odor and colorant stabilized compositions
EP4608518A1 (de) 2022-12-21 2025-09-03 Firmenich SA Mundpflegezusammensetzungen
AU2023460904A1 (en) 2023-08-04 2026-03-05 Symrise Ag Mycosporine-like amino acid analogue compounds and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3821221A (en) * 1970-08-25 1974-06-28 Delmar Chem 1,2,3,6-tetrahydropyrimidine-2-one compounds and processes for makingthem
JPH0887120A (ja) * 1994-09-19 1996-04-02 Fuji Electric Co Ltd 電子写真用感光体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100441535B1 (ko) * 1995-08-29 2004-10-08 베. 만 휘스 에쓰. 아. 청량제조성물,식용제품및향료조성물
EP1503763B1 (de) * 2002-05-02 2009-12-02 Cragmont Pharmaceuticals, LLC Therapeutische zusammensetzungen enthaltend 1,2,3,6-tetrahydropyrimidin-2-one und entsprechende methoden

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3821221A (en) * 1970-08-25 1974-06-28 Delmar Chem 1,2,3,6-tetrahydropyrimidine-2-one compounds and processes for makingthem
JPH0887120A (ja) * 1994-09-19 1996-04-02 Fuji Electric Co Ltd 電子写真用感光体

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Briffa, K. et al., Blowing Hot and Cold, Science, vol. 295; pp. 2227-2228, (2002).
Kim, C-H et al., Synthesis of Pyrimidin-2-one Nucleosides as Acid-Stable Inhibitors of Cytidine Deaminase, J. Med. Chem., 29:1364-1380, (1986).
McKerny, D. et al., Identification of a cold receptor reveals a general role for TRP channels in thermosensation, Nature, vol. 416; pp. 52-58, (2002).
Wei et al, "AG-3-5: A chemical producing sensations of cold", Journal of Pharmacy and Pharmacology (1983), 35(2), 110-112. *
Wei, E.T., et al.; AG-3-5: a chemical producing sensations of cold; J. Pharm. Pharmacol.; 35:110-112 (1983).
www.tocris.com/1531.htm printout-An Activator of the Novel Cold Receptor, CMR1.

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050090514A1 (en) * 2003-07-02 2005-04-28 Mark Reynolds Trp-p8 active compounds and therapeutic treatment methods
US7893072B2 (en) 2003-07-02 2011-02-22 Genentech, Inc. Trp-p8 active compounds and therapeutic treatment methods
US20070142798A1 (en) * 2005-12-16 2007-06-21 The Procter & Gamble Company Disposable absorbent article having serviceable indicia indicating improper fit
US8558053B2 (en) 2005-12-16 2013-10-15 The Procter & Gamble Company Disposable absorbent article having side panels with structurally, functionally and visually different regions
US8697938B2 (en) 2005-12-16 2014-04-15 The Procter & Gamble Company Disposable absorbent article having side panels with structurally, functionally and visually different regions
US8697937B2 (en) 2005-12-16 2014-04-15 The Procter & Gamble Company Disposable absorbent article having side panels with structurally, functionally and visually different regions
US9662250B2 (en) 2005-12-16 2017-05-30 The Procter & Gamble Company Disposable absorbent article having side panels with structurally, functionally and visually different regions
US20090110656A1 (en) * 2007-10-31 2009-04-30 Lemke Sarah A Skin cooling composition
US20090157153A1 (en) * 2007-12-13 2009-06-18 Sarah Anne Lemke Skin cooling system
US20100297038A1 (en) * 2008-01-17 2010-11-25 Givaudan S.A. Benzimidazole Derivatives And Their Use As Cooling Agents

Also Published As

Publication number Publication date
CN1694872A (zh) 2005-11-09
US20060106217A1 (en) 2006-05-18
RU2005111243A (ru) 2005-10-27
RU2334741C2 (ru) 2008-09-27
EP1546114B1 (de) 2015-09-30
BR0314447A (pt) 2005-07-19
WO2004026840A1 (en) 2004-04-01
JP4959939B2 (ja) 2012-06-27
AU2003266321A1 (en) 2004-04-08
EP1546114A1 (de) 2005-06-29
ZA200502122B (en) 2006-05-31
CN100506800C (zh) 2009-07-01
GB0221697D0 (en) 2002-10-30
JP2006512294A (ja) 2006-04-13
US20040067970A1 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
US20060106217A1 (en) Novel compounds and their uses
CA2734682C (en) Detection and use of low molecular-weight modulators of the cold-menthol receptor trpm8
US7030273B1 (en) Compounds with physiological cooling effect
CN101257949B (zh) 清凉化合物
JPWO1994010117A1 (ja) シクロヘキサノール誘導体，これを含有する冷感剤および冷感性組成物，並びに該誘導体の製造方法およびその中間体
CN101184470A (zh) 清凉化合物
KR20090113829A (ko) Ｎ-치환된-ｐ-멘탄-3-카복스아미드 및 이의 용도
WO2022171653A1 (en) Organic compounds as trpm8 activators
BRPI0609447A2 (pt) compostos refrescantes
EP1817000B1 (de) Thienopyrimidine als kühlmittel
CA2142671C (en) Composition for enhancing hair growth
JP7734665B2 (ja) 有機化合物
BRPI0709393A2 (pt) compostos 2-alcoxifenóis para -substituìdos, uso dos mesmos, método de fornecer um efeito refrescante à boca ou pele e produto contendo ditos compostos
US20060280697A1 (en) Composition
JPH05255186A (ja) ３−置換−ｐ−メンタン誘導体並びにこれを含有する 冷感剤
AU2016342264A1 (en) Synthesis of cyclohexane carboxamide derivatives useful as sensates in consumer products
EP0427625B1 (de) Interne Salze des 2,4-Diamino-6-alkoxy-3-sulphooxypyrmidium-Hydroxids und ihre Verwendung für die Behandlung und die Verhütung des Haarausfalls
CN109715594A (zh) 作为脱色剂或亮白剂的二氟化的化合物

Legal Events

Date Code Title Description
AS Assignment

Owner name: CONOPCO, INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FOSTER, ALISON JAYNE;VAN DER LOGT, CORNELIS PAUL ERIK;TAREILUS, ERWIN WERNER;REEL/FRAME:014241/0108;SIGNING DATES FROM 20030820 TO 20031001

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.)

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.)

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362